
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
The American Journal of Managed Care
over 23 years ago
Restoring Trust to Managed Care, Part 2: A Focus on Physiciansover 23 years ago
Review of the Newer Antiepileptic Drugs





